The best summer AC temperature? Experts have an unpopular answer.
Summer 2025 is here and temperatures are reaching dangerous levels, making air conditioning important for comfort and safety.
But what temperature should you set your thermostat at? The answer is a balancing act between energy savings, comfort and safety.
'It is essential to stay cool during hot weather — use air conditioning or go to a cool place where you feel comfortable,' Dr. Michelle Morse, New York City's acting health commissioner, said in a statement. 'Heat is dangerous, but taking certain precautions can prevent illness and protect your health.'
People also have bills to pay as AC demand skyrockets. Here are ways to stay cool while balancing budgets.
Summer 2025 brings killer heat. Here are some surprising ways to stay safe.
The best temperature to set your air conditioning is 78 degrees Fahrenheit when you wake up, according to the U.S. Environmental Protection Agency's Energy Star program. Energy companies in Florida, Maryland and Missouri also recommend thermostats at 78 degrees during summer months.
Not many people follow this recommendation, as a 2021 Consumer Reports survey showed. And a 2024 poll from the Detroit Free Press, part of the USA TODAY Network, found 72 degrees was a favorite among readers.
But setting your thermostat at a higher temperature can maximize efficiency.
As temperatures ideally drop at night, people should set thermostats 4 degrees warmer when they go to sleep.
If you're away from home, you can avoid unnecessary energy usage by setting temperatures 7 degrees warmer, the energy department said. Even 7 to 10 degrees, for around 8 hours daily, can save up to 10% annually on cooling and heating.
Since windows bring in heat, window curtains can help keep indoors cooler.
Look for air leaks — such as windows, baseboards and doors — and seal them to keep cool air in and hot air outside.
Reduce use of appliances that generate heat, such as stoves or ovens.
Use fans to circulate cool air, but don't use them as your only cooling device.
There are other methods to stay cool, which USA TODAY compiled here. You should also check on others who may be more vulnerable to heat-related illness, including young children, older people and people with chronic health issues.
If it gets too hot, look for a nearby cooling center. Even public areas, such as malls, museums or pools, can give critical respite.
Contributing: Jeanine Santucci and Greta Cross, USA TODAY.
Eduardo Cuevas is based in New York City. Reach him by email at emcuevas1@usatoday.com or on Signal at emcuevas.01.
This article originally appeared on USA TODAY: Experts say this is best AC temperature amid heat wave
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Cue Biopharma Receives FDA Feedback on Pre-IND Briefing Document Reinforcing Company's Intention to Advance IND Submission for CUE-401 to Address Unmet Need in the Treatment of Autoimmune Disease
CUE-401, a first-in-class bispecific molecule designed to induce and expand Tregs in vivo through the co-activity of transforming TGF-β and a modified variant of IL-2 BOSTON, June 24, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of autoimmune disease, today announced it has received Pre-Investigational New Drug (Pre-IND) feedback from the U.S. Food and Drug Administration (FDA). The FDA reviewed the first-in-human trial design, including the Company's plan for dose escalation, proposed populations and safety monitoring plan. On the basis of the FDA feedback, the Company, intends to file an IND pending completion of final IND enabling studies. CUE-401 is the Company's lead autoimmune asset, a first-in-class bispecific fusion protein/molecule designed to induce and expand regulatory T cells (Tregs) in vivo through the co-activity of transforming growth factor beta (TGF-β) and a modified variant of interleukin 2 (IL-2). 'We are highly encouraged by the FDA's positive feedback on our proposed development plan for this important program. We believe CUE-401, with its first-in-class mechanism exploiting the combined activities of TGF-β and IL-2 is a potentially disruptive approach differentiated from other Treg-directed therapies, and has the potential to provide durable, long-lasting immune rebalance and tolerance addressing multiple, significant disease indications,' said Daniel Passeri, chief executive officer of Cue Biopharma. Dr. Dan Baker, chief development officer of Cue Biopharma commented, 'CUE-401's mechanistic design extends beyond nTreg proliferation by transforming effector/autoreactive responses to an anti-inflammatory and/or suppressive response, with the prospects of establishing tolerance. The combination of interleukin 2 (IL-2) and transforming growth factor beta (TGF-ß) is considered the 'master switch' for conversion of activated T effector cells into T cells with a regulatory phenotype.' About CUE-401CUE-401 is a preclinical, bispecific fusion protein designed to induce and expand regulatory T cells (Tregs) through the co-activity of modified variants of transforming growth factor beta (TGF-β) and interleukin 2 (IL-2) with therapeutic potential across a range of T-cell mediated autoimmune and inflammatory diseases. CUE-401 has been engineered to harness the Treg induction capacity of TGF-β combined with IL-2 signaling to provide what Cue Biopharma believes to be superior quality and stability of Tregs. The design and specifications of CUE-401 have been guided by leading scientific publications demonstrating that both IL-2 and TGF-β are required for stable and efficient production of active and durable Tregs. CUE-401 is designed to overcome multiple hurdles required to exploit the therapeutic potential of a master switch with a first-in-class, bispecific molecule integrating a masked TGF-ß, with our clinically validated, attenuated IL-2 with an antibody Fc fragment. This novel design provides for 'conditional binding' and avoids off target activity, simplifies manufacturing and has highly differentiated findings in multiple pre-clinical models. In these models, CUE-401 behaves as a master switch to convert autoreactive effector T cells (inflammatory cells) into stable, induced T-regulatory cells (iTregs). These findings suggest that CUE-401 acts by establishing a 'tolerance positive feedback loop' that not only increases nonspecific Treg populations, but critically, reduces and converts specific autoreactive T cells into transdifferentiated iTregs that are specific for the disease-causing autoantigens. About Cue BiopharmaCue Biopharma, a clinical-stage biopharmaceutical company, is developing a novel class of injectable biologics to selectively engage and modulate disease-specific T cells directly within the patient's body. The company's proprietary platform, Immuno-STAT™ (Selective Targeting and Alteration of T cells), and biologics are designed to harness the curative potential of the body's intrinsic immune system without the adverse effects of broad systemic immune in Boston, Massachusetts, we are led by an experienced management team with deep expertise in immunology and immuno-oncology as well as the design and clinical development of protein biologics. For more information please visit and follow us on X and LinkedIn. Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, those regarding: the company's expectations regarding the planned IND filing for CUE-401; the Company' expectations regarding the potential characteristics and benefit of CUE-401; the company's belief that the Immuno-STAT platform stimulates targeted immune modulation through the selective modulation of disease-relevant T cell and the applicability of the company's platform across many cancers and autoimmune diseases; and the company's business strategies, plans and prospects. Forward-looking statements, which are based on certain assumptions and describe the company's future plans, strategies and expectations, can generally be identified by the use of forward-looking terms such as 'believe,' 'expect,' 'may,' 'will,' 'should,' 'would,' 'could,' 'seek,' 'intend,' 'plan,' 'goal,' 'project,' 'estimate,' 'anticipate,' 'strategy,' 'future,' 'likely' or other comparable terms, although not all forward-looking statements contain these identifying words. All statements other than statements of historical facts included in this press release regarding the company's pipeline of product candidates and platforms, and its strategies, prospects, plans and objectives are forward-looking statements. Important factors that could cause the company's actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the Company's ability to successfully advance is development plan for CUE-401; potential setbacks in the company's research and development efforts including negative or inconclusive results from its preclinical studies or clinical trials or the company's ability to replicate in later clinical trials positive results found in preclinical studies and early-stage clinical trials of its product candidates; serious and unexpected drug-related side effects or other safety issues experienced by participants in clinical trials; its ability to secure required U.S. Food and Drug Administration ('FDA') or other governmental approvals for its product candidates, including FDA clearance of any future IND submission for CUE-401, and the breadth of any approved indication; adverse effects caused by public health pandemics, including possible effects on the company's trials; delays and changes in regulatory requirements, policy and guidelines including potential delays in submitting required regulatory applications to the FDA; the company's reliance on licensors, collaborators, contract research organizations, suppliers and other business partners; the company's ability to obtain adequate financing to fund its business operations in the near term; the company's ability to maintain and enforce necessary patent and other intellectual property protection; competitive factors; general economic and market conditions and the other risks and uncertainties described in the Risk Factors and in Management's Discussion and Analysis of Financial Condition and Results of Operations sections of the company's most recently filed Annual Report on Form 10-K and any subsequently filed Quarterly Report(s) on Form 10-Q. Any forward-looking statement made by the company in this press release is based only on information currently available to the company and speaks only as of the date on which it is made. The company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise. Investor Contact Marie Campinell Senior Director, Corporate CommunicationsCue Biopharma, Media ContactJonathan PappasLifeSci Communicationsjpappas@
CBS News
an hour ago
- CBS News
Wisconsin Supreme Court sides with environmentalists in fight over PFAS "forever chemicals"
How scientists are working to clean up PFAS How scientists are working to clean up PFAS How scientists are working to clean up PFAS The Wisconsin Supreme Court delivered a victory for environmentalists on Tuesday in the fight over "forever chemicals" known as PFAS, issuing a ruling that advocates said will hold polluters accountable. The liberal-controlled court ruled that state regulators can force landowners to clean up emerging pollutants such as PFAS before they are officially designated as hazardous substances. The 5-2 ruling is a defeat for the state's powerful group representing businesses and manufacturers, which had argued the state couldn't enforce regulations on substances before they were officially designated as hazardous. It is the latest development in a yearslong battle in Wisconsin and nationally involving regulators, environmentalists, politicians and businesses over how to deal with PFAS contamination. Cities large and small across Wisconsin, from Madison to Marinette and La Crosse to Wausau, are grappling with PFAS contamination. PFAS, or perfluoroalkyl and polyfluoroalkyl substances, are a group of chemicals that have been around for decades and have now spread into the nation's air, water and soil. The chemicals helped eggs slide across nonstick frying pans, ensured that firefighting foam suffocates flames and helped clothes withstand the rain and keep people dry. They resist breaking down, however, which means they stay around in the environment and have a hard time breaking down in the body. There is a wide range of health harms now associated with exposure to certain PFAS, including low birth weight, cancer and liver disease. The Wisconsin Supreme Court ruled in a case brought by the state's largest business group, Wisconsin Manufacturers & Commerce, which sued the DNR in 2021 on behalf of Leather Rich, a dry cleaning business in Oconomowoc. Leather Rich became aware of PFAS contamination in 2018 and was working on cleaning it up when the DNR posted a message online in 2019 saying it now considered PFAS chemicals a hazardous substance. The agency ordered the dry cleaner to test its groundwater for PFAS but didn't tell the business which compounds it needed to test for or what levels would be considered dangerous. Leather Rich argued the DNR can't force businesses to test and clean up contamination from emerging pollutants like PFAS without first designating them as hazardous substances. That process can take years and requires approval from the Legislature. All that time, polluters could harm the environment and put people's health and safety at risk with no obligation to begin cleanup, the DNR argued. A Waukesha County judge and the state appeals court sided with Leather Rich. The DNR appealed, saying the lower court's ruling would neuter the state's "spills law," which was designed to confront pollution. That law, enacted about 50 years ago, requires anyone who causes, possesses or controls a hazardous substance that's been released into the environment to clean it up. "Wisconsin's Spills Law safeguards human health and the environment in real time by directly regulating parties responsible for a hazardous substance discharge," Justice Janet Protasiewicz wrote for the majority. No state law required the DNR to implement a rule before requiring Leather Rich to begin cleaning up the site, she wrote. "The DNR has explicit authority to enforce a threshold for reporting the discharge of hazardous substances," Protasiewicz wrote. The court's four liberal justices were joined by conservative Justice Brian Hagedorn in the majority. Conservative justices Annette Ziegler and Rebecca Bradley dissented. They said the ruling allows bureaucrats to "impose rules and penalties on the governed without advance notice, oversight, or deliberation. In doing so, the majority violates three first principles fundamental to preserving the rule of law — and liberty." Democratic Gov. Tony Evers and environmental advocates hailed the decision. Evers called it "a historic victory for the people of Wisconsin and my administration's fight against PFAS and other harmful contaminants." Rob Lee, attorney for Midwest Environmental Advocates, called the ruling "a victory for the health and wellbeing of the people of Wisconsin" that reinforces "a bedrock environmental and public health protection that has kept Wisconsinites safe from toxic contamination for almost fifty years." But Scott Manley, a vice president at WMC, said the ruling leaves it up to businesses and homeowners to guess about what is hazardous, leaving them subject to "crushing fines and endless, costly litigation." "This ruling blesses a regulatory approach that is fundamentally unfair, unworkable, and impossible to comply with," Manley said. Federal regulators placed the first-ever national standards on PFAS in drinking water last year, but the Trump administration said in May that it planned to weaken those limits. The state has imposed less restrictive limits on PFAS in surface and drinking water, defined as piped water delivered through public systems and noncommunity systems that serve places such as factories, schools and hotels. But it has not implemented PFAS standards for groundwater, the source of drinking water for about two-thirds of Wisconsin residents. The agency stopped efforts to draft them in 2023 after determining that compliance would be too expensive.
CNN
an hour ago
- CNN
Inside the MAHA movement, ‘Alligator Alcatraz,' toxic masculinity: Catch up on the day's stories
5 Things Food & health Animal storiesFacebookTweetLink Follow 👋 Welcome to 5 Things PM! A majority of Americans disapprove of President Donald Trump's decision to launch airstrikes against Iran, according to a new CNN poll. Sharp partisan divides cut through nearly every question asked in the survey. Here's what else you might have missed during your busy day. 1️⃣ MAHA movement: Major food and agricultural groups are publicly positioning themselves as fans of the 'Make America Healthy Again' campaign, with brands of all stripes rushing to seize this moment for change. Supporters advocate for 'clean' ingredients, cutting out sugar and saying no to food dyes. 2️⃣ 'Alligator Alcatraz': To carry out more of Trump's promised mass deportations, Florida has started construction on a migrant detention facility that it's billing as 'efficient' and 'low-cost' — because Mother Nature will provide much of the security. 3️⃣ Handle with care: Ripping the plastic wrap from the meat or prepackaged fruit and veggies you bought at the grocery store may contaminate your food, new research found. So can opening and closing plastic bottle caps. 4️⃣ AI startup: Perplexity seems to have caught the attention of two of the largest and most influential tech companies. The search tool uses artificial intelligence models to parse web content and curate answers. Here's what it can do. 5️⃣ Toxic masculinity: Long before Harry Styles caused a stir by wearing a Gucci dress on the cover of Vogue, another music and style icon pushed back against binary fashion norms. Remember Kurt Cobain's dainty floral frock? Get '5 Things' in your inbox If your day doesn't start until you're up to speed on the latest headlines, then let us introduce you to your new favorite morning fix. Sign up here for the '5 Things' newsletter. 🦷 H2-Oh: CNN Chief Medical Correspondent Dr. Sanjay Gupta answers questions about filtering out fluoride from your tap water and explains why it's not really necessary. • Exclusive: Early US intel assessment suggests strikes on Iran did not destroy nuclear sites• Cuomo and Mamdani are the focus of the final hours of New York City's mayoral primary• Tropical Storm Andrea becomes first named system of the Atlantic hurricane season 🏀 That's the average increase in value of WNBA franchises during the past year. The 13 teams are collectively worth $3.5 billion, according to Sportico. 🎨 Artistic inspiration: For some people, Instagram's infinite scroll is an endless time waster. For Moka Lee, it's the main source of ideas for her portrait paintings. 'If you can rent Venice for your wedding you can pay more taxes.' Message on a tarp with an image of Jeff Bezos 💬 Change of plans: Protesters in Venice rallying against the impending nuptials of the billionaire Amazon founder and journalist Lauren Sanchez claimed victory after their threats of disruption reportedly prompted a different wedding venue. ✈️ The National Transportation Safety Board just issued a report on the mid-flight blowout of a door plug on a flight last year on which airline?A. DeltaB. AlaskaC. SpiritD. Southwest⬇️ Scroll down for the answer. ⚾ Welcome back! Former Chicago Cubs great Sammy Sosa made his long-anticipated return to the place where he used to hit towering home runs and flash his big smile. The fans gave the organization's all-time home runs leader a warm welcome in his first time back at Wrigley Field since 2004. 👋 We'll see you tomorrow.🧠 Quiz answer: B. The blowout occurred minutes into a January 2024 flight on Alaska Airlines.📧 Check out all of CNN's newsletters. Today's 5 Things PM was edited and produced by CNN's Kimberly Richardson and Emily Scolnick.
